- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| NEWCELX Aktie jetzt für 0€ handeln | |||||
| 27.05. | NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes | 494 | GlobeNewswire (Europe) | Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. ("NewcelX"; Nasdaq:... ► Artikel lesen | |
| 27.05. | NewcelX Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 27.05. | EXCLUSIVE: NewcelX Advances Diabetes Therapy Toward Human Trials With FDA Pre-IND Submission | 2 | Benzinga.com | ||
| 06.05. | NewcelX akquiriert bis zu 3,4 Millionen Dollar | 1 | punkt4.info | ||
| 01.05. | NLS Pharmaceutics GAAP EPS of -$2.16 | 1 | Seeking Alpha | ||
| 30.04. | NewcelX Ltd.: NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026 | 386 | GlobeNewswire (Europe) | NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term... ► Artikel lesen | |
| 30.04. | EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug | 3 | Benzinga.com | ||
| 30.04. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 20.04. | NewcelX informiert über Fortschritte bei Diabetes-Therapie-Kooperation | 2 | Investing.com Deutsch | ||
| 20.04. | NewcelX updates presentation on diabetes therapy collaboration | 3 | Investing.com | ||
| 20.04. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.04. | NewcelX Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 01.04. | NewcelX prices $1.35M equity financing | 1 | Seeking Alpha | ||
| 01.04. | NewcelX sichert sich 1,35 Mio. US-Dollar durch Privatplatzierung mit 30 % Aufschlag | 16 | Investing.com Deutsch | ||
| 01.04. | NewcelX raises $1.35M in private placement at 30% premium | 2 | Investing.com | ||
| 01.04. | NewcelX Ltd.: NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing | 3 | GlobeNewswire (USA) | ||
| 10.03. | NewcelX and Eledon partner for NCEL-101 programme | 4 | Pharmaceutical Technology | ||
| 09.03. | NewcelX Enters Strategic Collaboration With Eledon Pharma | - | RTTNews | ||
| 09.03. | NewcelX, Eledon Partner to Advance a Potential Functional Cure for Type 1 Diabetes | 1 | Contract Pharma |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,642 | +1,09 % | Aktien - Shortseller-Positionen: Carl Zeiss Meditec, Evotec, HelloFresh, Kontron, LPKF Laser, TeamViewer | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| MODERNA | 40,135 | +0,88 % | Opening Bell: Bitcoin, Strategy, Broadcom, Marvell, Micron, Axon Enterprise, Moderna, Lululemon | Die US-Börsen haben am Donnerstag eine zweigeteilte Entwicklung gezeigt. Der Dow Jones eröffnete mit klaren Gewinnen, baute diese im Verlauf deutlich aus und schloss 1,73 Prozent fester. Der Nasdaq... ► Artikel lesen | |
| VALNEVA | 2,215 | +0,36 % | BRANDMELDUNG bei Valneva: Warum Insider bereits massiv kaufen - So reagieren erfahrene Anleger jetzt | ||
| PALATIN TECHNOLOGIES | 13,500 | -1,03 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| VIVOSIM LABS | 1,160 | -1,69 % | VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders | RICHMOND, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company, today announced that, after extensive consideration of the... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 11,000 | +4,17 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,570 | +0,28 % | Arbutus Biopharma Corp - S-8, Securities to be offered to employees in employee benefit plans | ||
| XOMA ROYALTY | 36,000 | 0,00 % | Weekly Buzz: FDA Okays AstraZeneca's Saphnelo Pen, EC Clears Crinetics Pharmaceuticals' Acromegaly Drug, Soligenix Slumps, Ligand Snaps Up XOMA Royalty | BASEL (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals in the US and Europe, acquisitions, and a few trial halts, alongside positive data readouts spanning multiple therapeutic... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,260 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer | OCALA, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today reported positive progress in a mid-year update from the ongoing Phase 2 clinical... ► Artikel lesen | |
| NOVOCURE | 14,335 | -0,59 % | NovoCure Ltd - 8-K, Current Report | ||
| PHARMING | 1,081 | -0,14 % | Pharming Group N.V.: Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja (leniolisib) to treat children aged 4 to 11 years with APDS | If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiency Supplemental... ► Artikel lesen | |
| CYTOKINETICS | 59,24 | +1,89 % | Cytokinetics, Incorporated: Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program | ||
| TRAWS PHARMA | 1,250 | 0,00 % | Traws Pharma, Inc.: Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks | Broad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a... ► Artikel lesen |
Das Unternehmen NEWCELX LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,170 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEWCELX LTD finden Sie auf Wallstreet Online.